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Background & Aims: Infectious diarrhea caused by vi-
ruses plus enterotoxigenic bacteria is often more
severe than diarrhea induced by either pathogen alone.
We postulated that the increased cell adenosine 38,58-
cyclic monophosphate (cAMP) concentration observed
during infection by enterotoxigenic organisms retards
the intestinal repair process by blocking activation of
mitogen-activated protein kinases (MAPKs) in prolifer-
ating intestinal cells. Methods: We evaluated the ef-
fects of glutamine on MAPK activity, thymidine incorpo-
ration, and cell number in glutamine-starved and
-sufficient rat intestinal crypt cells (IEC-6). Results: In
glutamine-starved cells, 10 mmol/L glutamine in the
absence of serum stimulated [3H]thymidine incorpora-
tion 8-fold. This effect was inhibited by 60% with
8-(4-chlorophenylthio) (8-CPT)-cAMP (100 mmol/L) 1
isobutyl methylxanthine (100 mmol/L). In cells not
starved of glutamine, glutamine stimulated thymi-
dine incorporation by 3-fold, and 8-CPT-cAMP com-
pletely blocked the mitogenic effect. Inhibition of
proliferation by cAMP persisted for at least 68 hours
after cAMP removal. In vitro kinase assays showed that
glutamine signaling requires an intact ERK (extra-
cellular signal–related kinase) pathway in unstarved
cells. In starved cells, at least one other pathway (JNK)
was activated by glutamine, and the mitogenic inhibi-
tion by 8-CPT-cAMP was incomplete. Other intestinal
fuels (glucose and acetate) were not mitogenic.
Conclusions: Increased levels of intracellular cAMP
inhibit ERKs but only partially reduce glutamine-
stimulated proliferation in enterocytes adapted to low
glutamine.
Viruses induce diarrhea by damaging the intestine,whereas enterotoxigenic bacteria elaborate toxins
that induce intestinal salt and water secretion without
injuring the mucosa. Diarrhea caused by viruses plus
enterotoxigenic Escherichia coli is more severe than diar-
rhea induced by either agent alone.1–4 Repair of the
intestinal epithelium is facilitated by luminal growth
factors, such as epidermal growth factor (EGF), transform-
ing growth factor (TGF)-a, and insulin-like growth
factor I, which are present in breast milk and interact
with specific membrane receptors.5 Many of these factors
activate protein kinases (MAPKs), such as the extracellu-
lar signal–related kinases (ERKs) ERK-1 and ERK-2, as
the initial step in signal transduction.6,7 Another mem-
ber of the MAPK family that may participate in inflam-
mation and repair is c-Jun nuclear kinase (JNK, also
called stress-activated protein kinase, SAPK). JNK phos-
phorylates and activates the nuclear transcription factor
c-Jun. ERKs phosphorylate and activate Elk-1 and other
transcription factors.6,8,9
Not only is there good evidence that MAPKs are
activated by many types of mitogenic signals, but
dominant mutations of Raf-1,10 MEK-1, and ERKs
inhibit NIH-3T3 cell proliferation. Activating muta-
tions of MEK-1 produced accelerated proliferation.11
Adenosine 38,58-cyclic monophosphate (cAMP) has inhibi-
tory or stimulatory effects on MAPK level and prolifera-
tion in a cell-type specific manner (reviewed by Graves
and Lawrence12). cAMP may inhibit signal transduction
through the MAPK pathway (Rat-1 cells)13–15 or the
JNK pathway (T lymphocytes).16 We hypothesized that
cAMP would also inhibit crypt cell proliferation, and we
tested the ability of the trophic nutrient glutamine
(GLN) to stimulate enterocyte proliferation in the pres-
ence of increased cAMP concentrations. The results of
these studies have been presented in part previously.17
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glutathione S-transferase; JNK, c-Jun nuclear kinase; MAPK, mitogen-
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Acrylamide and bisacrylamide were obtained from
National Diagnostics (Atlanta, GA), glutathione-Sepharose
from Pharmacia Biotechnology (Piscataway, NJ), and anti-
ERK antibody from Santa Cruz Biotechnology (Santa Cruz,
CA). Protease and phosphatase inhibitors (aprotinin, leupeptin,
bestatin, 4-nitrophenyl phosphate, pepstatin, Pefabloc, dithio-
threitol, and Nonidet P-40 [NP-40]) were from Boehringer
Mannheim (Indianapolis, IN). PD98059 was from Calbiochem-
Novabiochem (San Diego, CA). [3H]Thymidine was obtained
from Amersham (Arlington Heights, IL). [g-32P]Adenosine
triphosphate (ATP) was purchased from DuPont (Boston, MA).
All other chemicals were obtained from Sigma Chemical Co.
(St. Louis, MO).
Cells
We studied the nontransformed crypt cell line IEC-6
(ATCC, Gaithersburg, MD) at passage 9–20. Cells were grown
in Dulbecco’s modified Eagle medium (DMEM) with 4.5 g/L
glucose, 0.5 U/mL bovine insulin, and 5% fetal calf serum




IEC-6 cells were plated in 24-well plates at a seeding
density of 5 3 104 cells per well. Six hours after plating, cells
were synchronized by serum starvation in DMEM–low glucose
(DMEM-L) with no serum, low glucose (5 mmol/L), and
‘‘serum’’ levels of GLN (0.7 mmol/L) or no GLN for 18 hours.
Cells were then treated for 24 hours. [3H]Thymidine (2 µCi)
was incubated with treatments. Perchloric acid in methanol
(0.5 mL of 4 mol/L) was then added, and cellular proteins were
allowed to precipitate overnight. The pellet was dissolved in
Scintisafe Econo2 (Fisher Scientific, Fair Lawn, NJ) and
counted in a b-scintillation counter (Beckman, Fullerton, CA).
Raf Kinase, MEK, and ERK Immune
Complex Assay
IEC-6 cells (70% confluent) were starved of serum and
GLN overnight. After exposure to GLN or inhibitors, cells
were washed twice with cold phosphate-buffered saline (PBS).
Lysis buffer (20 mmol/L Tris, pH 7.5, 10% glycerol, 1% Triton
X-100, 137 mmol/L NaCl, and 2 mmol/L EDTA) was added.
Cells were scraped and collected in a microcentrifuge tube,
centrifuged, and transferred to new tubes. Two micrograms of
monoclonal antibody (anti–Raf C-12, rabbit polyclonal anti–
MEK-1, or goat polyclonal anti-ERK2; Santa Cruz Biotechnol-
ogy) was added, and the tubes were rolled at 4°C for 1.5 hours.
Protein A (Santa Cruz Biotechnology) slurry was added into
each tube, and tubes were again rolled for 40 minutes. Beads
were washed twice with cold lysis buffer and twice with cold
PBS. For the Raf assay, 5 µL recombinant MEK (100 µg/mL)
was added, along with 0.3 µmol/L ATP and 6 µg bovine serum
albumin. The mixture was shaken at 30°C for 10 minutes.
For both the Raf and MEK assays, ERK-2 (20 µg/mL, 5 µL)
was added for 10 minutes. For the ERK assay, 20 µL of 20
mmol/L HEPES, pH 7.5, was added to the beads. Finally, 20
µL of a mixture containing 75 µmol/L cold ATP, 2 µCi/mL hot
ATP, and 10 µg of myelin basic protein was added, and the
mixture was incubated for an additional 10 minutes. The
reaction was stopped by adding 20 µL EDTA (100 mmol/L, pH
7.5). Tubes were centifuged briefly, and 40 µL was spotted onto
P-81 filter paper (Whatman distributor; Hillsboro, OR).
Papers were washed in 10% phosphoric acid for 10 minutes 6
times. Papers were rinsed in 100% ethyl alcohol (EtOH) and
dried with a hair drier before liquid scintillation counting.
In Vitro Assays of Cellular JNK
and ERK Activity
Cells were collected with a cell lifter in Dignam C
buffer (420 mmol/L NaCl, 1.5 mmol/L MgCl2, 20 mmol/L
HEPES [pH 7.0], 0.2 mmol/L EDTA, 25% glycerol, and 0.5
mmol/L dithiothreitol) plus protease/phosphatase inhibitors
(0.5 mmol/L Pefabloc, 0.1 mmol/L 4-nitrophenyl phosphate,
0.04 mmol/L b-glycerophosphate, 0.05 mmol/L Na3VO4, 40
µg/mL bestatin, 2 µg/mL aprotinin, 0.54 µg/mL leupeptin, and
0.7 µg/mL pepstatin A). We used a solid-phase assay with a
glutathione S-transferase (GST)–c-Jun or GST-Elk fusion pro-
tein as the substrate.18 GST-cElk plasmid was a gift of R.
Treisman (Transcription Laboratory, Imperial Cancer Research
Fund, London, England); GST-cJun plasmid was a gift of M.
Karin (University of California, San Diego). Substrate (1 µg)
was linked to GLN-Sepharose. For the JNK assay, 25 µg of
whole cell extract was mixed with the substrate, 1 µg of
GST–c-Jun, in 300 µL HBB (20 mmol/L HEPES, pH 7.7, 50
mmol/L NaCl, 0.1 mmol/L EDTA, 2.5 mmol/L MgCl2 , 0.5%
Triton X-100, plus protease/phosphatase inhibitors), at 4°C for
3 hours. The GST-bound proteins were then washed 4 times
with HBB and incubated with 4 mmol/L HEPES, 2 mmol/L
MgCl2, 4 mmol/L b-glycerophosphate, 0.2 mmol/L dithiothre-
itol, 10 µmol/L Na3VO4 , 2 mmol/L p-nitrophenylphosphate,
and 2 µmol/L ATP (with [g-32P]ATP . 4000 Ci/mmol), at
30°C for 30 minutes. The phosphorylated c-Jun fusion protein
was boiled in sodium dodecyl sulfate (SDS) sample buffer and
loaded onto a 10% SDS–polyacrylamide gel with molecular-
weight standards. Equal loading was verified by Coomassie
blue staining. Autoradiography/densitometry was used to
quantify labeled GST-Jun.
For the ERK assay, 5 µg anti-Erk antibody mixture with
protein A–Sepharose in RIPA (150 mmol/L NaCl, 50 mmol/L
Tris-Cl [pH 7.2]), 1% deoxycholate, 1% Triton X-100, and
0.1% SDS (plus protease/phosphatase inhibitors) were rotated
for 2 hours at 4°C. The mixture was sequentially washed once
with 10% sucrose RIPA, HBNP (20 mmol/L HEPES [pH 7.5],
50 mmol/L NaCl, 0.1 mmol/L EDTA, 2.5 mmol/L MgCl2, and
0.5% NP-40), HB (HBNP without NP-40), and kinase
reaction buffers (20 mmol/L HEPES [pH 7.5], 10 mmol/L
MgCl2, 2 mmol/L dithiothreitol, 0.1 mmol/L Na3VO4, 25
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mmol/L b-glycerophosphate, and 10 mmol/L 4-nitrophenyl
phosphate) and then incubated with 1 µg substrate in 25 µL of
kinase reaction buffer for 30 minutes at 30°C and washed 3
times with 13 RIPA. The phosphorylation products were run
on a 12.5% SDS–polyacrylamide gel. The gel was dried, and
autoradiography with Phosphorimager analysis was used to
quantify density of the bands.
Oxygen Consumption
After 16 hours of serum starvation, IEC-6 cells were
trypsinized and collected in DMEM-L medium. We incubated
5 3 106 cells in 1 mL DMEM-L medium in water-jacketed
vials with continuous stirring at 37°C. After 2 minutes’
equilibration with air and 10 µL GLN with or without
8-(4-chlorophenylthio) (8-CPT)-cAMP, PD98059, or aminooxy-
acetate (AOA), the system was sealed and oxygen consumption
(QO2) was measured by a polarographic Clarke electrode for 10
minutes. The preliminary data showed that cell QO2 was stable
for 15 minutes and then decreased slowly. Results are expressed
as percent oxygen consumed per million cells per minute.
Cell Cycle Study
Cell culture and treatment followed the [3H]thymidine
incorporation protocols. After treatment, cells were washed
with cold PBS twice and then were trypsinized, centrifuged,
and resuspended in a small volume of PBS. Ice-cold EtOH (700
µL) was added for 5 minutes, and the cells were then washed
twice with cold PBS. Cold propidium iodide solution (500 µL,
concentration of 50 mg/mL with 2 µg/mL ribonuclease and
0.1% Triton X-100) was added to 107 cells. Fluorescence was
analyzed with a Becton Dickinson FACScan flow cytometer
(San Jose, CA). Single-perimeter histograms were collected on
100,000 single cells. Doublets were eliminated by pulse
analysis.
Cell Counting Study
Cells were grown in culture, starved, and treated for
these studies in the same manner as described in the [3H]thymi-
dine experiments. Cells were counted after 10 minutes of
trypsinization in a hemacytometer. Cells in each well were
counted twice.
Statistics
Results are expressed as means 6 SE. Effects of
treatment were assessed by the 1-way analysis of variance.
Individual groups were compared with the post hoc Tukey test
(SigmaStat; Jandel Scientific, San Rafael, CA).
Results
Effect of GLN and 8-CPT-cAMP on DNA
Synthesis Rate of IEC-6 Cells
Cells were preincubated overnight in either a
‘‘starvation medium’’ without serum or GLN (to maxi-
mize the response to GLN19) or in serum-free medium
with 0.7 mmol/L GLN to mimic the GLN concentration
in plasma (‘‘sufficient’’). GLN-sufficient cells responded
to 10 mmol/L20 GLN with a 3.8 6 0.3–fold increase in
[3H]thymidine incorporation, whereas in starved cells
thymidine incorporation increased 8.5 6 0.2–fold (n 5
3–4 observations). Total thymidine incorporation 24
hours after addition of 10 mmol/L GLN was similar in
both GLN-starved or -sufficient cells: about 8-fold
greater than thymidine incorporation in GLN-starved
cells.1
We hypothesized that elevated 8-CPT-cAMP levels
would inhibit MAPKs and thereby reduce the intestinal
cell proliferative response to GLN.19 cAMP inhibited the
thymidine incorporation of IEC-6 cells after addition of
10 mmol/L GLN in a concentration-dependent manner
(Figure 1A). The slopes of the cAMP dose-effect relation-
ships for starved and sufficient cells showed that cAMP
inhibition was greater in the sufficient cells, with 100%
inhibition of GLN-stimulated thymidine incorporation
at 100 µmol/L 8-CPT-cAMP.
We compared the effects of GLN with EGF on
[3H]thymidine incorporation with or without cAMP
(Figure 1B). EGF (without GLN) stimulated [3H]thymi-
dine incorporation 2.2 6 0.2–fold above rate of incorpo-
ration in starved cells; this effect was blocked (97%
inhibition) by 8-CPT-cAMP (n 5 11 observations from 3
passages of cells; not shown). In GLN-sufficient (0.7
mmol/L) cells, EGF stimulated [3H]thymidine incorpora-
tion 3.8-fold; this effect was also completely inhibited by
8-CPT-cAMP.
Effect of cAMP on MAPK Induction
by GLN and EGF
We compared the effects of GLN with or without
3-CPT-cAMP on ERK and JNK induction. cAMP has
been shown to inhibit their activation in many cell
types.13–15,21 For the ERK assay, we used an in vitro
kinase assay of whole-cell extracts, with the nuclear target
of ERK-1 and -2, GST-Elk, as the substrate. In these
studies, cells were preincubated in nonstarvation media
with 0.7 mmol/L GLN and subsequently exposed to
GLN or a positive control, EGF, for 5, 15, or 30 minutes.
Other cells were exposed to GLN or EGF, plus 8-CPT-
cAMP (300 µmol/L) with isobutyl methylxanthine
(IBMX; 100 µmol/L).
GLN signals through ERKs in IEC-6 cells19 (Figure
2A). Elk phosphorylation increased significantly to 3.1 6
0.3 of control levels at 5 minutes after GLN exposure
(P , 0.05). This effect was significantly reduced in cells
exposed to 8-CPT-cAMP (, 40% inhibition; P , 0.05).
At 15 and 30 minutes, the level of ERK activity declined
and was only slightly affected by 8-CPT-cAMP.
EGF treatment produced a maximal (5.0 6 1.5–fold)
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activation of kinase activity at 5 minutes. (Figure 2; P ,
0.05). This stimulatory effect was inhibited 66% by
coincubation of the cells with 8-CPT-cAMP (P , 0.05).
The EGF treatment had a biphasic stimulatory effect.
ERK activity was increased at 15 minutes by 3.9 6
1.3–fold and at 30 minutes by 4.8 6 0.3–fold (P , 0.05
at 30 minutes). At 15 minutes, 8-CPT-cAMP inhibited
the EGF effect by 50%, whereas 8-CPT-cAMP inhibition
was 100% at 30 minutes (P , 0.05). The means of 3
experiments at 5 and 30 minutes are shown in the bar
graph in Figure 2C.
Effect of EGF and GLN on Raf Activity in
IEC-6 Cells
Raf kinase is the tyrosine-threonine kinase in the
ERK pathway that is activated by Ras after EGF and
insulin receptor activation.22 Raf has been proposed to be
a major site for regulation of ERK activity by cAMP (via
protein kinase A) and is inhibited by cAMP in many cell
types.12 In IEC-6 cells, EGF stimulated Raf kinase
14-fold, an effect that at 5 minutes was inhibited 75% by
8-CPT-cAMP (Figure 3). Raf continued to be activated
15 minutes after EGF treatment, by 9-fold, an effect
blocked by 8-CPT-cAMP pretreatment (data not shown).
Figure 3 shows that Raf phosphorylation/activation is not
stimulated by GLN in IEC-6 cells.
Effect of GLN on MEK Activity in IEC-6 Cells
These results suggested that GLN activated an
Raf-independent pathway; therefore, we examined MEK
activation by GLN. MEK, also called mitogen-activated
protein kinase kinase, is immediately ‘‘downstream’’ of
Raf in the signaling cascade. Figure 4 shows that GLN
activates MEK almost as effectively as EGF in IEC-6
cells, with a 2-fold activation at 5 minutes. As shown in
the inset, the effect of GLN on MEK persisted with MEK
stimulation by 1.6–1.7-fold at 15 and 40 minutes (P ,
0.05). This effect of GLN was blocked by 8-CPT-cAMP
(Figure 4).
Recently, a synthetic inhibitor, PD98059, has been
developed that is specific for MEK. PD98059 does not
block JNK or p38 MAPK activity in other cell types.23
PD98059 fully inhibits phenotypic changes attributed to
MAPK activation in other cell types. As shown in Figure
4, PD98059 (50 µmol/L) completely inhibited GLN-
stimulated MEK at 5 minutes.
b
Figure 1. (A) Effects of GLN and 8-CPT-cAMP on 24-hour IEC-6 cell
proliferation. Three hours after plating IEC-6 cells (,40% confluent) in
24-well plates, the cells were starved in serum-free DMEM-L and
pretreated with GLN (0.7 mmol/L;g) or without GLN (n) for 16 hours.
Cells were then stimulated with 10 mmol/L GLN for 24 hours.
8-CPT-cAMP (0–100 µmol/L) with IBMX (100 µmol/L) was added to
the medium 15 minutes before GLN treatment. [Methyl-H3]thymidine
(2 µL; sp act, 2.96 TBq/mmol, 80.0 Ci/mmol) was added at the same
time. Counts incorporated into perchloric acid–insoluble material are
shown as multiples of control group (group treated with 0 mmol/L
8-CPT-cAMP). (B) Effect of 8-CPT-cAMP on 24-hour IEC-6 cell prolifera-
tion stimulated by EGF. h, EGF; 4, EGF 1 cAMP. Cells were either
starved overnight of GLN or pretreated with 0.7 mmol/L GLN in
serum-free DMEM-L, and the GLN concentration was maintained after
20 ng/mL EGF was added. Twenty-four hours later, [3H]thymidine
incorporation into acid-insoluble material was quantified as above. In
paired plates, cells were exposed to EGF 1 8-CPT-cAMP (1024 mol/L) 1
IBMX (100 µmol/L). Data are compared with control cells. On the left
side, control cells were pretreated with 0.7 mmol/L GLN without EGF
or 8-CPT-cAMP; thymidine incorporation rate was 19,800 cpm, and the
rate increased 3.8 6 0.6–fold after EGF treatment. After EGF 1
8-CPT-cAMP treatment, the rate decreased to 0.5 6 0.02–fold of
control. **P , 0.01 compared with EGF alone. On the right side,
control cells were treated overnight with 0 mmol/L GLN, and [3H]thymi-
dine incorporation was 12,830 cpm. Treatment with EGF increased
[3H]thymidine incorporation 2.01 6 0.4–fold, whereas treatment with
EGF 1 8-CPT-cAMP reduced [3H]thymidine incorporation to 0.6 6
0.1–fold the control value. *P , 0.05 compared with EGF alone; n 5
4. Control cells had baseline [3H]thymidine cpm of 1000–7000
without GLN pretreatment and 5000–30,000 cpm with 0.7 mmol/L
GLN pretreatment.
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We have found that GLN has a much more potent
impact on thymidine incorporation when cells are starved
of serum and GLN overnight.19 Therefore, we deter-
mined if ERK signaling in GLN-‘‘starved’’ cells is more
effective or more resistant to PD98059 compared with
control cells. Figure 5 shows that GLN and EGF
activations of ERKs are similar in starved (left side) and
unstarved cells (right side). Furthermore, PD98059 is an
effective inhibitor of MEK (and therefore the ERK
pathway) regardless of GLN preexposure or starvation.
Effect of GLN Oxidation on MEK Activation
in IEC-6 Cells
We used AOA (10 mmol/L), an inhibitor of
transaminase reactions, to prevent conversion of GLN-
derived glutamate to a-ketoglutarate and to inhibit the
glutaminase reaction by producing a buildup of gluta-
mate. We showed previously that AOA blocks GLN
induction of ornithine decarboxylase, an enzyme impli-
cated in cell proliferation.20 Figure 6 shows that 10
mmol/L GLN stimulates QO2 by IEC-6 cells by 2-fold.
Stimulation was fully blocked by 10 mmol/L AOA. AOA
also completely inhibited MEK activation by GLN at 5
minutes (Figure 4).
We also determined if inhibition of MAPK signaling
interferes with GLN’s oxidative metabolism. Figure 6
shows that GLN stimulation of QO2 was not signifi-
cantly reduced by 8-CPT-cAMP (300 µmol/L) or
PD98059 (50 µmol/L).
PD98059 and 8-CPT-cAMP: Effects on
GLN-Stimulated IEC-6 Cell Proliferation
We hypothesized that the early inhibition in ERK
and MEK signaling in cells exposed to 8-CPT-cAMP
would have a significant impact on subsequent DNA
synthesis rate. 8-CPT-cAMP or PD98059 inhibited 10
A B
Figure 2. Effects of GLN, EGF, and cAMP on ERK activity of IEC-6 cells.
Cells (,70 % confluent) in 100-mm plastic dishes were starved in
DMEM-L without GLN or serum for 24 hours and then were treated with
(A) 10 mmol/L GLN or (B) 20 ng/mL EGF with or without 8-CPT-cAMP
(with IBMX) for 5, 15 or 30 minutes. Cell samples were collected after
washing twice in Dignam C buffer and were allowed to phosphorylate
GST-Elk beads in the presence of [32P]ATP after immunoprecipitation
with anti-ERK specific antiserum. Phosphorylated GST-Elk was heated
and separated by 12.5% SDS–polyacrylamide gel electrophoresis.
Equal loading was determined by Coomassie blue staining. Dried gel
was exposed to film for 3 days. The gel is representative of 3
experiments. (C) Averaged densitometry values (means 20 6 SEM).
*P , 0.05 compared with control cell ERK activity. cAMP completely
blocked ERK activation by GLN at 5 minutes and by EGF at 5 and 30
minutes.
Figure 3. Effect of EGF and GLN on Raf kinase activity in IEC-6 cells.
Cell were starved as described in Figure 2. In 1 group of cells, cAMP
(333 µmol/L 1 100 µmol/L IBMX) was added 15 minutes before EGF
(20 ng/mL). After 5 minutes, cell lysates were collected and used for
an immune complex assay for Raf (described in Materials and
Methods). The increase in kinase activity above that of unstimulated
cells is shown. n 5 2–3 except for EGF-stimulated cells, where n 5 1.
Control cpm, 3140.
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mmol/L GLN-stimulated thymidine incorporation to a
similar extent (54% inhibition by 8-CPT-cAMP, 65%
inhibition by PD98059) in GLN-starved IEC-6 cells
(Figure 7, left panels). In GLN-sufficient enterocytes (0.7
mmol/L GLN pretreated), 8-CPT-cAMP or PD 98059
completely blocked the GLN stimulation and reduced
DNA synthesis below basal levels (right panels).
To determine if inhibitors of cell proliferation had
toxic effects on cultured intestinal cells, we treated cells
with 8-CPT-cAMP 1 IBMX or PD98059 for 24 hours,
and we counted nonviable cells that take up trypan blue
(1:50 dilution, 5-minute exposure, n 5 500 cells, 2
passages). Control cells deprived of GLN and serum had
94.5% viability. PD98059 (50 µmol/L)-treated cells had
92.3% viability. Of cells treated with 8-CPT-cAMP (300
µmol/L) 1 IBMX (100 µmol/L), 96.4% remained viable.
In summary, we found no evidence that either 8-CPT-
cAMP or PD98059 was toxic.
GLN is a precursor of purines and pyrimidines.24 To
confirm that GLN stimulates IEC-6 cell proliferation,
rather than thymidine incorporation into DNA alone, we
plated cells at a density of 105 cells/well and manually
counted cells after trypsinization 24 hours later. Table 1
shows that GLN increased cell number by 68% (P ,
0.05). This stimulation was blocked by cAMP and
PD98059. Note that cells shifted from a glucose concen-
tration of 5.5 mmol/L (DMEM-L) to a concentration of
25 mmol/L in the absence of GLN had no increase in cell
number. Similarly, the addition of the intestinal fuel25
acetic acid (10 mmol/L) did not stimulate mitogenesis.
(Acetic acid at this concentration decreased the pH of the
media by 0.4 pH units, which could have partially
reduced a mitogenic effect.)
Figure 4. Effects of GLN on MEK activity of IEC-6 cells: inhibition by
8-CPT-cAMP, MEK inhibitor PD98059, and GLN metabolism inhibitor
AOA. MEK is the substrate of Raf and has been shown to phosphory-
late ERK-1 and ERK-2. Cells were starved as described in Figure 2.
PD98058 (50 µmol/L), 8-CPT-cAMP (333 µmol/L 1 100 µmol/L IBMX,
‘‘cAMP’’), and AOA (10 mmol/L) were added 15 minutes before GLN
(10 mmol/L) and EGF (20 ng/mL) were added. After 5 minutes of GLN
or EGF treatment, collected cell lysates were used for an immune
complex assay with myelin basic protein as the substrate (see
Materials and Methods). n 5 2. *P , 0.05 compared with control
cells. n 5 3–4 observations for each treatment; cpm for control cells,
2460. Inset shows kinetics of GLN-stimulated MEK activation (fold of
control level).
Figure 5. Effect of PD98059 on ERK activity of GLN-starved or
GLN-sufficient cells. Whole-cell extracts were prepared from IEC-6
cells starved of GLN overnight or pretreated with 0.7 mmol/L GLN and
subsequently exposed to GLN (G, 10 mmol/L) or EGF (E, 20 ng/mL) or
no treatment (control, C) for 10 minutes. In vitro ERK activity was
assayed with GST-Elk as the substrate. Some preparations were
exposed to GLN or EGF combined with PD98059 (PD, 50 µmol/L).
Relative densitometry values are shown at the top. One of 2 similar
blots.
Figure 6. Effect of AOA, cAMP, and PD98059 on GLN-stimulated QO2
by IEC-6 cells. After 24-hour starvation, 5 3 106 IEC-6 cells in DMEM-L
were equilibrated with air for 2 minutes in a continuously stirred
chamber with a Clarke-type electrode for the detection of PO2. Vehicle
(control) or an agent in vehicle was added, and QO2 was recorded for 8
minutes. Cells were exposed to vehicle or agent only once. Represen-
tative traces are shown for each treatment with means for 4 replica-
tions below. Treatments were as follows: Control, GLN-starved; GLN
10 mmol/L; GLN 1 8-cpt-cAMP, 300 µmol/L; GLN 1 PD98059, 50
µmol/L ; GLN 1 AOA, 10 mmol/L.
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Effect of 8-CPT-cAMP on GLN
Activation of JNK
To determine if the 8-CPT-cAMP–resistant prolif-
eration in starved IEC-6 cells could be related to
stimulation of the stress-activated protein kinase (SAPK),
Jun nuclear kinase (JNK), cells were treated with 10
mmol/L GLN for 30 minutes after overnight starvation
and JNK was determined. As a positive control, we used
TNF-a (10 ng/mL) to enhance JNK acitivity. JNK
activity was assessed by an in vitro kinase assay that uses
GST-cJun N-terminus as the substrate (n 5 2). Figure 8
shows that 10 mmol/L GLN with or without TNF-a
increased JNK ,4-fold. 8-CPT-cAMP did not inhibit
either GLN or TNF-a–stimulated JNK activity.
Effect of 8-CPT-cAMP Inhibition on the
G1/S Transition of the Enterocyte Cell Cycle
We sorted cells by fluorescence-activation to deter-
mine the effect of 8-CPT-cAMP on the cell cycle. Cells
were made quiescent by GLN/serum starvation over-
night, and the next day the media was changed to media
with GLN with or without 8-CPT-cAMP. As shown in
Figure 9, 8-CPT-cAMP arrested progression of GLN-
sufficient cells through the cycle, with accumulation in
G1 and depletion of cells in G2 (P , 0.05; n 5 3). Table 2
shows that GLN starvation also produces a G1/S arrest.
Duration of cAMP and PD98059 Inhibition
of Proliferation
To determine if cell proliferation inhibition by
cAMP and PD98059 is reversible, IEC-6 cells were
treated with cAMP or PD98059 for 4–24 hours; subse-
quently, cAMP and PD98059 were washed out (Figure
10). Cells were allowed to recover without GLN for 8–20
hours before GLN stimulation. Cells were then counted
after GLN (10 mmol/L) treatment for 24 hours (Figure
10A) and 48 hours (Figure 10B). cAMP-treated cells did
not recover despite washout of up to 20 hours and
subsequent GLN treatment for 24 or 48 hours. PD98059-
treated cells similarly did not begin to proliferate after up
Figure 7. Effect of GLN, cAMP, and PD98059 on proliferation of
GLN-starved and -sufficient IEC-6 cells. Cell starvation and thymidine
incorporation assay were identical to those shown in Figure 1. cAMP
(333 µmol/L) and PD98059 (50 µmol/L) were added 15 minutes
before GLN (10 mmol/L); thymidine incorporation at 24 hours esti-
mated the cellular DNA synthesis rate. On the left, the 3 bars (upper
and lower) show results from GLN-starved cells before stimulation
with GLN. On the right, the 3 bars show data from cells pretreated
overnight with 0.7 mmol/L GLN. *P , 0.05 and **P , 0.01 compared
with control (DMEM-L without GLN). 1P , 0.05 compared with 0.07
mmol/L GLN (n 5 4). Control cpm is described in Figure 1.
Figure 8. Effects of GLN, TNF-a, and 8-CPT-cAMP on c-JUN kinase
activity in IEC-6 cells. Cells in 100-mm dishes (70% confluent) were
starved in DMEM-L without serum or GLN for 24 hours. They were
subsequently treated with 10 mmol/L GLN. TNF-a (10 ng/mL) was
added as a positive control. Cells in lanes 3 and 5 were exposed to
8-CPT-cAMP (333 µmol/L) 1 IBMX (100 µmol/L) for 10 minutes. Then
the cells were washed and lysed by rotating in Dignam C buffer. Lysate
(25 µg) was coincubated with GST–c-Jun in the presence of [32P]ATP.
Labeled GST–c-Jun was separated by 10% SDS–polyacrylamide gel
electrophoresis. Coomassie blue staining showed equal loading.
Results are representative of 2 blots.
















Mean 1.82 3.06a 1.95 2.35 1.88 1.91
SEM 0.24 0.23 0.20 0.20 0.17 0.18
NOTE. IEC-6 cells (105) were plated in 24-well plates overnight in
DMEM-L without GLN or serum (DMEM-L, DMEM with 5.5 mmol/L
glucose). The next day, nutrients with or without inhibitors were added
for 24 hours, and cell number was counted 24 hours later. n 5 6 for
each treatment. 8-CPT-cAMP concentration is 1024 mmol/L, com-
bined with 100 µmol/L IBMX. PD98059 concentration is 50 µmol/L.
n 5 6 observations.
aP , 0.05 compared with DMEM-L.
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to 20 hours of PD98059 washout, followed by 24 hours
of GLN treatment. However, by 48 hours of GLN, cells
treated 68 hours earlier with a 4-hour pulse of PD98059
did show recovery. Cells exposed to PD98059 56 hours
earlier showed no significant increase in cell number
compared with control cells (GLN-and serum-starved). In
these studies, cell number never exceeded 3.3 3 105, because
cells had reached confluence at this density. These results were
not biased by cells reaching confluence, because cells were
only 80%–85% confluent at 24 hours and were ,95%
confluent by 48 hours. The poor reversibility of the cAMP
effect could be caused by sequestration of 8-CPT-cAMP
within the cells, for example by cAMP-binding proteins.
Discussion
The major new findings of this report are (1) L-
glutamine stimulates intestinal cell proliferation in ‘‘starved’’
intestinal cells, and this mitogenic effect is partially inhibited
by blocking of ERK signaling; (2) cAMP inhibits prolifera-
tion in cultured small intestinal cell lines and, like the MEK
inhibitor PD98059, inhibits ERKs; (3) GLN stimulates
ERK signaling through its metabolism; and (4) GLN
signals through an Raf-independent mechanism.
GLN and Proliferation of Starved Cells
Intense interest has focused on GLN as a ‘‘nutraceu-
tical’’ to enhance bowel function. Recent reports show
GLN is trophic in the intestine,26,27 whereas others find
no GLN effect on villus morphology.28–30 In general,
minimal effects of GLN have been found in well-
nourished animals with bowel resection and in well-
nourished rats or humans receiving total parenteral
nutrition supplemented with GLN.30,31 Trophic effects
dominate reports about starved animals. For example,
starved rats that are subsequently fed GLN-supple-
Figure 9. Effect of GLN and cAMP on the cell cycle of cultured
enterocytes. After starvation and treatment as described in Figure 1,
cells were fixed in EtOH, stained with propidium iodide, and analyzed
on a fluorescence-activated cell scanner. Single-perimeter histograms
of 100,000 events were collected on aliquots of cells treated with
GLN 1 8-CPT-cAMP or GLN. The coefficient of variance of the G0–1
(‘‘resting phase’’) peaks for both conditions was ,5.0. S, S phase. An
overlay of the 2 histograms shows the lack of progression through the
cell cycle to the G2 stage in cells treated with 8-CPT-cAMP 1 GLN (n 5
3). No obvious evidence for apoptosis is shown.









G1 79 6 1 73 6 4 85 6 0
S 10 6 1 9 6 1 7 6 1
G2 12 6 2 18 6 5a 8 6 1
NOTE. IEC-6 cells were grown to 80% confluence and 6 hours later
were exposed overnight to ‘‘starvation’’ conditions (no GLN or serum),
GLN (10 mmol/L), or GLN 1 8-CPT-cAMP. Cells were then subjected to
fluorescence-activated cell sorting. Data are means 6 SEM of 3
observations.
aP , 0.05 compared with GLN 1 8-CPT-cAMP.
Figure 10. Determination of reversibility of cAMP inhibition and
PD98059 inhibition of IEC-6 cell proliferation. Cells were plated in
24-well plastic plates at a density of 105 cells/well, washed, treated,
and counted manually after trypsin treatment. Control cells were kept
in DMEM-L. GLN was added at 10 mmol/L. The 3 numbers beneath
each bar refer to (1) the time (hour) of cAMP/IBMX or PD98059
treatment; (2) the length of time of ‘‘washout’’; and (3) the time (hour)
of GLN treatment. Cells were counted (A) 24 hours and (B) 48 hours
after GLN treatment (n 5 6; *P , 0.05).
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mented total parenteral nutrition32 and rats fed a GLN-
supplemented diet after abdominal irradiation33 have a
more normal intestinal villous architecture.
GLN metabolism has myriad physiological effects in
this tissue. GLN fuels intestinal oxidative metabolism;
serves as a precursor for nucleotide, arginine, and poly-
amine biosynthesis; and enhances intestinal blood flow.24
Our findings support the concept that EGF is much more
potent than GLN in mitogenic signaling, whereas GLN
is a mandatory cofactor for downstream effects (e.g.,
thymidine incorporation) of EGF. GLN is an essential
substrate for carbamoyl phosphate synthetase II (CPS II),
the enzyme that catalyzes conversion of GLN to car-
bamoyl phosphate, an initial step in pyrimidine synthe-
sis.34 Given that DMEM contains 10 mmol/L glucose but
no nucleotides or nucleosides, we speculate that a primary
effect of GLN is to provide nucleotides for DNA
synthesis. However, GLN utilization for nucleotides
would not explain GLN’s rapid activation of the ERK or
JNK pathways, or the ,50% increase in [3H]thymidine
incorporation observed in GLN-sufficient (3.5 mmol/L)
enterocytes when reexposed to GLN.19 These findings
point to a nonnutritive ‘‘trigger’’ or signaling effect of
GLN on intestinal cell proliferation.
cAMP Inhibits Intestinal Cell Proliferation
Our interest in 8-CPT-cAMP originated from the
observation that increased intestinal mucosal 8-CPT-
cAMP concentration is characteristic of not only toxi-
genic diarrhea (e.g., cholera) but also inflammatory
enteropathies such as salmonellosis, when mucosal prosta-
glandin levels are high.35 In cholera toxin–exposed rabbit
ileal loops, mucosal 8-CPT-cAMP content is increased to
,1 µmol/L, compared with less than half this value in
control tissues. These values appear lower than the
maximal concentrations needed to block proliferation in
crypt enterocytes, but 8-CPT-cAMP may have leaked
rapidly from cells used for these assays. Levels in rapidly
washed upper crypt cells in Salmonella-induced enteritis
reached as high as 50 pmol/mg protein,35 or about 5
µmol/L, assuming mucosal protein content is about 10
g/dL. This value is well within the range that inhibits
proliferation in IEC-6 cells (Figure 1). It would be
interesting to know if intestinal mucosal 8-CPT-cAMP
levels remain elevated in children with chronic enteropa-
thy and delayed villus repair.
Cell proliferation can be stimulated or inhibited by
8-CPT-cAMP in a cell-specific manner.12 cAMP ‘‘blocked’’
small intestinal IEC-6 cells at the G1/S transition, an
observation previously reported in other epithelial cells.36
A possible site of inhibition in our studies is at the level
of Raf and/or MEK, and our studies showed these kinases
were inhibited by cAMP, as shown in previous investiga-
tions of mesenchymal cell lines.13,14
cAMP and PD98059 Effects
on ERKs and JNK
MAPKs are proline-directed kinases that are
activated by phosphorylation of tyrosine and threonine
residues. Three classes of MAPKs have been identified,
which share considerable sequence homology and are
often, but not always, regulated in parallel during
mitogenesis or cell injury: the ERKs (extracellular signal–
related kinases), the stress-activated protein kinase c-Jun
N-terminal kinase (JNK), and p38 MAPK, which is also
activated by osmotic and other cellular stresses and
during cell motility. This and our previous studies
showed that GLN stimulates ERK functional activity in
enterocytes.19 It is likely that the ERKs were a major site
of inhibition of proliferation in 8-CPT-cAMP–treated
cells in the present studies. Additional sites of inhibition
by 8-CPT-cAMP are possible, resulting in inhibition of
transition into S-phase of the cell cycle.
Inhibition of proliferation by 8-CPT-cAMP could have
been mediated by inhibition of cellular processes such as
mitochondrial metabolism or cytoskeletal rearrangement
(independent of 8-CPT-cAMP effects on the ERK path-
way). However, mitochondrial QO2 was not affected by
8-CPT-cAMP. Furthermore, PD98059, a highly specific
inhibitor of MEK1 (the upstream activator of ERK-1 and
-2)23,37 completely blocked GLN- or EGF-stimulated
proliferation and inhibited Elk-1 phosphorylation in
nonstarved IEC-6 cells, without altering QO2. The
inhibition of EGF-induced proliferation and ERK activ-
ity in IEC-6 cells by PD98059 has been demonstrated
recently.38
It is possible that cAMP inhibits proliferation through
mechanisms in addition to ERK inhibition. cAMP has
been shown to produce cell cycle arrest by inhibiting the
action of cdk-activating kinase and by increasing the
activity of the cdk inhibitor p27Kip1.39 However, in that
study, murine BAC1.2F5A macrophages were arrested at
both G1/S and in G2, whereas in our studies intestinal
IEC-6 cells were arrested only in G1/S. Also, the similar-
ity between MEK inhibition by PD98059 and the effects
of 8-CPT-cAMP suggests that a significant component of
the cAMP inhibition is through MAP kinases. Addition-
ally, we cannot rule out effects of 8-CPT-cAMP and
PD98059 on cell viability, but general toxicity of these
inhibitors was ruled out by exclusion of trypan blue by
IEC-6 cells exposed to 8-CPT-cAMP or PD98059.
We could not find previous studies examining activa-
tion of JNKs in small intestinal cell lines. Our studies
showed that JNK is activated by mitogenic stimuli.19
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JNKs may be activated during hyperthermia and oxidant
stress, and are activated during apoptosis.40 Interestingly,
recent studies from the laboratory of Ko et al.41 have
shown that GLN starvation induces apoptosis in IEC-6
cells. In our GLN-starved cells, JNK was not activated
initially, although there was activation after GLN treat-
ment. Although there is no known specific inhibitor of
the JNK pathway, the use of PD98059 allowed us to
separate 2 MAPK pathways activated by GLN in prolifer-
ating IEC-6 cells. We found no significant effect of
PD98059 on JNK activity (not shown) and only a partial
effect of PD98059 in reducing [3H]thymidine incorpora-
tion response to GLN in ‘‘stressed’’ (starved) IEC-6 cells.
While our studies demonstrate an effect of GLN on JNK
in the starved cells, they do not rule out an effect of GLN
on other pathways such as protein kinase C, phosphoino-
sitol-3-kinase, or p38 MAPK.
GLN Metabolism Bypasses Raf to
Stimulate MEK and ERK Induction
EGF, insulin, and other growth factors are known
to activate MEK via Raf recruitment to membrane-
bound ras, and Raf activation. There is evidence that
growth signals may stimulate ERK activation in the
absence of Raf activation (Figures 3 and 4). In fact, MEK
is often activated without a corresponding increase in Raf
kinase activity.12 One example is in G protein–coupled
signal transduction in vascular smooth muscle cells. In
these cells, angiotensin II stimulates ERK activation by
an Ras- and Raf-independent pathway requiring activa-
tion of protein kinase C.42
We do not know the mechanism for initiation of
GLN-stimulated mitogenesis. Research in other cell
types suggests several possibilities. Kilberg et al.43
showed that amino acid starvation induced derepression
of system A amino acid transport activity within 2 hours.
Amino acid refeeding (with A system amino acids or
GLN) increased cellular proliferation when added after
starvation, perhaps by an effect on intracellular amino
acid ‘‘loading.’’ Additionally, cytosolic GLN, aspartate,
and aminoisobutyrate repressed ribosomal protein messen-
ger RNA levels.43 When cells were starved and subse-
quently refed, increased messenger RNA translation was
observed. Other possibilities for how GLN signals mito-
genesis include GLN-stimulated release of paracrine
growth factors stored in a rapidly released pool, or a rapid
increase in polyamine synthesis via ornithine decarboxyl-
ase induction.20
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